SOLICITATION 36C26124Q0180.docx

36C26124Q0180

PAGE 1 OF

1. REQUISITION NO.

2. CONTRACT NO.

3. AWARD/EFFECTIVE DATE

4. ORDER NO.

5. SOLICITATION NUMBER

6. SOLICITATION ISSUE DATE

a. NAME

b. TELEPHONE NO. (No Collect Calls)

8. OFFER DUE DATE/LOCAL

TIME

9. ISSUED BY

CODE

10. THIS ACQUISITION IS

UNRESTRICTED OR

SET ASIDE:

% FOR:

SMALL BUSINESS

HUBZONE SMALL

BUSINESS

SERVICE-DISABLED

VETERAN-OWNED

SMALL BUSINESS

WOMEN-OWNED SMALL BUSINESS

(WOSB) ELIGIBLE UNDER THE WOMEN-OWNED

SMALL BUSINESS PROGRAM

EDWOSB

8(A)

NAICS:

SIZE STANDARD:

11. DELIVERY FOR FOB DESTINA-

TION UNLESS BLOCK IS

MARKED

SEE SCHEDULE

12. DISCOUNT TERMS

13a. THIS CONTRACT IS A

RATED ORDER UNDER

DPAS (15 CFR 700)

13b. RATING

14. METHOD OF SOLICITATION

RFQ

IFB

RFP

15. DELIVER TO

CODE

16. ADMINISTERED BY

CODE

17a. CONTRACTOR/OFFEROR

CODE

FACILITY CODE

18a. PAYMENT WILL BE MADE BY

CODE

TELEPHONE NO.

UEI:

EFT:

PHONE:

FAX:

17b. CHECK IF REMITTANCE IS DIFFERENT AND PUT SUCH ADDRESS IN OFFER 18b. SUBMIT INVOICES TO ADDRESS SHOWN IN BLOCK 18a UNLESS BLOCK BELOW IS CHECKED

SEE ADDENDUM

19.

20.

21.

22.

23.

24.

ITEM NO.

SCHEDULE OF SUPPLIES/SERVICES

QUANTITY

UNIT

UNIT PRICE

AMOUNT

(Use Reverse and/or Attach Additional Sheets as Necessary)

25. ACCOUNTING AND APPROPRIATION DATA

26. TOTAL AWARD AMOUNT (For Govt. Use Only) 27a. SOLICITATION INCORPORATES BY REFERENCE FAR 52.212-1, 52.212-4. FAR 52.212-3 AND 52.212-5 ARE ATTACHED. ADDENDA

ARE

ARE NOT ATTACHED.

27b. CONTRACT/PURCHASE ORDER INCORPORATES BY REFERENCE FAR 52.212-4. FAR 52.212-5 IS ATTACHED. ADDENDA

ARE

ARE NOT ATTACHED

28. CONTRACTOR IS REQUIRED TO SIGN THIS DOCUMENT AND RETURN _______________

29. AWARD OF CONTRACT: REF. ___________________________________ OFFER

COPIES TO ISSUING OFFICE. CONTRACTOR AGREES TO FURNISH AND

DATED ________________________________. YOUR OFFER ON SOLICITATION

DELIVER ALL ITEMS SET FORTH OR OTHERWISE IDENTIFIED ABOVE AND ON ANY

(BLOCK 5), INCLUDING ANY ADDITIONS OR CHANGES WHICH ARE

ADDITIONAL SHEETS SUBJECT TO THE TERMS AND CONDITIONS SPECIFIED

SET FORTH HEREIN IS ACCEPTED AS TO ITEMS:

30a. SIGNATURE OF OFFEROR/CONTRACTOR 31a. UNITED STATES OF AMERICA (SIGNATURE OF CONTRACTING OFFICER) 30b. NAME AND TITLE OF SIGNER (TYPE OR PRINT) 30c. DATE SIGNED 31b. NAME OF CONTRACTING OFFICER (TYPE OR PRINT) 31c. DATE SIGNED

AUTHORIZED FOR LOCAL REPRODUCTION

(REV. NOV 2021)

PREVIOUS EDITION IS NOT USABLE

Prescribed by GSA - FAR (48 CFR) 53.212

7. FOR SOLICITATION

INFORMATION CALL:

STANDARD FORM 1449

SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES

OFFEROR TO COMPLETE BLOCKS 12, 17, 23, 24, & 30

593-24-1-055-0171

36C261-24-AP-0415

36C26124Q0180 01-17-2024

LEAH SMITH

702-791-9000 105065 01-24-2024

11:00 AM

PST

36C261 Department of Veterans Affairs Network Contracting Office 21 VA Southern Nevada Healthcare System 6900 N. Pecos Road, Building 6 North Las Vegas NV 89086

X

325412 1250 Employees

N/A

See Delivery Schedule

36C261 Department of Veterans Affairs Network Contracting Office 21 Southern Nevada Healthcare System 6900 N. Pecos Road, Building 6 North Las Vegas NV 89086

Financial Services Center P.O. Box 149971

Austin TX 78714-9971

See CONTINUATION Page

CONTINGENCY HAZARDOUS PHARMACEUTICAL COMPOUNDING

SEE PRICE/COST SCHEDULE

This is a FAR Part 13 solicitation. Please see provisions 52.212-1 Instructions to Quoters and 52.212-2 Evaluation for important information regarding submitting your offer and how your offer will be evaluated.

Responses are due to Leah Smith at leah.smith@va.gov no later than the due date/time in box 8. Any questions must be received one (1) business day prior to this closing period.

See CONTINUATION Page

DAVID ALVAREZ

Contracting Officer

Table of Contents

SECTION B - CONTINUATION OF SF 1449 BLOCKS

B.1 CONTRACT ADMINISTRATION DATA

1. Contract Administration: All contract administration matters will be handled by the following individuals:

a. CONTRACTOR:

b. GOVERNMENT: Contracting Officer 36C261 David Alvarez

Network Contracting Office 21 VA Southern Nevada Healthcare System 6900 N. Pecos Road, Building 6 North Las Vegas NV 89086

2. CONTRACTOR REMITTANCE ADDRESS: All payments by the Government to the contractor will be made in accordance with:

3. INVOICES: Invoices shall be submitted in arrears:

4. GOVERNMENT INVOICE ADDRESS: All Invoices from the contractor shall be submitted electronically in accordance with VAAR Clause 852.232-72 Electronic Submission of Payment Requests.

All invoices from the contractor shall be submitted electronically in accordance with VAAR Clause 852.232-72 Electronic Submission of Payment Requests. VA's Electronic Invoice Presentment and Payment System - The FSC uses a third-party contractor, Tungsten, to transition vendors from paper to electronic invoice submission. Please go to this website:

http://www.tungsten-network.com/US/en/veterans-affairs/ to register and begin submitting electronic invoices, free of charge. The Department of Veterans Affairs Tungsten Number is: AAA544240062 (this allows you to file invoices online for free.)

More information on the VA Financial Services Center is available at: http://www.fsc.va.gov/einvoice.asp.

Vendor e-Invoice Set-Up Information:

If you have questions about the e-invoicing program or Tungsten, please contact the FSC at the phone number or email address listed below:

• Tungsten e-Invoice Setup Information: 1-877-489-6135

• Tungsten e-Invoice email: VA.Registration@Tungsten-Network.com

• FSC e-Invoice Contact Information: 1-877-353-9791

• FSC e-invoice email: vafsccshd@va.gov

ACKNOWLEDGMENT OF AMENDMENTS: The offeror acknowledges receipt of amendments to the Solicitation numbered and dated as follows:

B.2 STATEMENT OF WORK

Veterans Affairs Southern Nevada Healthcare System

1. CONTRACT TITLE: Pharmacy Hazardous Compounding Contingency

REQUIREMENTS/SCOPE: The Department of Veterans Affairs Southern Nevada Healthcare System (VASNHCS) is seeking a vendor for a firm fixed price contract to provide the compounding and delivery of antineoplastic hazardous drugs from an FDA 503A compliant facility on a contingency basis for patients receiving treatment and infusion services at VASNHCS.

The interested vendor must be able to provide the entire list of compounded chemotherapy medications on an as needed basis with terms and conditions as stated below.

There will be approximately up to 15 patients on any given day, Monday through Friday for chemotherapy infusion for any week of the year. The vendor must be able to supply and deliver all compounded chemotherapy medications listed below. All orders to be placed on an as needed basis by VASNHCS.

REQUIREMENTS

1. Vendor must be able to compound and provide hazardous medications for VASNHCS; approximately up to 15 patients on any given day, Monday through Friday, throughout the performance period. The medications required are included in, but not limited to, those stated in the Cost/Price Schedule.

2. All medications must be delivered with no less than 12 hours remaining on the Beyond-Use-Dating (BUD).

3. All compounding, labeling, and BUD will be based off USP 797, USP 800, and Federal Law.

4. Vendor must have a certified 503A pharmacy with an active Board of Pharmacy license that is able to ship to/within the State of Nevada.

5. Vendor must complete and meet all requirements for VA Pharmacy Benefits Management (PBM) Compounded Sterile Products Assessment Guidelines.

6. Vendor must be able to provide documentation of compliance with the standards outlined in the current version of USP 797 and USP 800.

7. Vendor must provide any survey or inspection results and responses from the Joint Commission, Board of Pharmacy, FDA, or any other governing body upon request.

8. Vendor must be able to provide stability data for all medications upon request.

9. Vendor must provide any certification reports for the sterile compounding areas and compounding hoods upon request. In the event of any failures, vendor must notify VASNHCS, provide action plans for the correction of deficiencies, and provide testing results showing the failures have been corrected within five business days.

10. Vendor must notify VASNHCS about anticipated shortages/recalls/discontinuations of medications.

11. Vendor must be able to ensure and provide documentation that medications are handled appropriately per the manufacturer’s specifications prior to the receipt of the medication by VASNHCS.

12. Medications must be stored and used in accordance with directions on FDA approved labeling.

13. Orders from VASNHCS will be submitted to vendor by 12:00pm PST via secure network or fax for next day delivery.

14. Orders from VASNHCS submitted to vendor after 12:00pm PST will be considered STAT and incur additional charges if next business day delivery is available for that order. STAT orders will be placed via secure network or fax and followed up with a telephone call to vendor to ensure availability.

15. Compounded medications will be transported via courier, overnight mail service, or any other means necessary as defined by the vendor to ensure receipt of medications prior to infusion date/time to VASNHCS. All medications and supplies will be packed for transport in such a manner that will insure acceptance by common carriers and safe delivery to VASNHCS. Packaged medications will comply with regulations of carriers as applicable to the mode of transportation.

16. All compounded medications will be delivered to the following address:

VA Southern Nevada Healthcare System 119-Inpatient Pharmacy 6900 North Pecos Road North Las Vegas, NV 89086

17. All compounded medications will be delivered to VASNHCS by 9:00am the first business day after orders are submitted.

18. Vendor will use specific supplies to be compatible with VASNHCS pumps and equipment.

a. Primary IV Set: BD Alaris: Pump Infusion Set Tubing (REF CH2426-0007)

b. In-Line Filters: Low Sorbing Extension Set 0.2 micron low Protein Binding Filter (REF:20350E)

c. Special Priming: Prime tubing with base fluid prior to adding medication

d. Total Volume Calculations: Per order if specified

e. Close System Transfer Device: BD PhaSeal

2. SPECIFIC TASKS:

Compounding and delivery of antineoplastic hazardous drugs from an FDA 503A compliant facility on a contingency basis, Monday through Friday for any week of the year. Up to 15 patients per day, with potentially multiple compounded medications needed per patient.

3. PERIOD OF PERFORMANCE/SCHEDULE:

The period of performance for this contract shall be from February 1, 2024 – September 30, 2026.

Orders from VASNHCS submitted to vendor after 12:00pm PST will be considered STAT and incur additional charges if next business day delivery is available for that order. STAT orders will be placed via secure network or fax and followed up with a telephone call to vendor to ensure availability.

Compounded medications will be transported via courier, overnight mail service, or any other means necessary as defined by the vendor to ensure receipt of medications prior to infusion date/time to VASNHCS. All medications and supplies will be packed for transport in such a manner that will insure acceptance by common carriers and safe delivery to VASNHCS. Packaged medications will comply with regulations of carriers as applicable to the mode of transportation.

All compounded medications will be delivered to the following address:

VA Southern Nevada Healthcare System 119-Inpatient Pharmacy Room 1D340 6900 North Pecos Road North Las Vegas, NV 89086

All compounded medications will be delivered to VASNHCS by 9:00am the following business day after orders are submitted.

4. PARTICIPATING FACILITY:

VA Southern Nevada Healthcare System 119-Inpatient Pharmacy Room 1D340 6900 North Pecos Road North Las Vegas, NV 89086

5. VA Facility Point of Contact The VA Facility Point of Contact (POC) shall provide general instructions and shall be responsible for ensuring invoices are certified for payment in a timely manner. Facility POC name and contact information shall be provided upon award.

6. CONTRACTOR POINT OF CONTACT:

a. Contractor shall designate one employee as the Contractor Point of Contact (POC) responsible for administrative matters in the performance of services under this contract. The Contractor POC shall have full authority to act for the Contractor on all matters relating to the daily performance of this contract.

b. The Contractor POC shall be available by telephone Monday through Friday, between 08:00 a.m. and 4:30 p.m. excluding national holidays.

c. Contractor shall provide the name and telephone number of the person designated as Contractor Point of Contact, Contractor Alternate Point of Contact, and the name, location and telephone number of the office where normal and emergency service calls are to be placed:

Point of Contact (Full Name):

Telephone Number:

E-mail Address:

Alternate Point of Contact (Full Name):

Telephone Number:

E-mail Address:

Emergency Service Contact Information:

Emergency Service Telephone Number:

7. U.S. GOVERNMENT FURNISHED MATERIALS AND SERVICES:

The contractor shall be responsible for the receipt and handling of all equipment and materials. The contractor shall coordinate proposed delivery areas with pharmacy.

8. CONTRACTOR FURNISHED ITEMS AND SERVICES:

The contractor shall furnish all necessary medications, materials and products. The contractor shall provide delivery for medication via national carrier.

9. RE-PERFORMANCE:

If product or delivery does not conform to the contract specifications, the Facility POC or the Contracting Officer shall require the Contractor to provide again to conform to the contract specifications, at no cost to the Government. When the defects in cannot be corrected by re-performance, the VA Medical facility may require the Contractor to call in a senior technical engineer from the manufacturer or from a different company. The Contractor shall incur and absorb all expenses for consultation outside the Contractor’s organization.

10. NATIONAL HOLIDAYS:

The Contractor is not required to provide delivery or pick up services on the following National Holidays.

When a holiday falls on a Sunday, the following Monday shall be observed as a legal holiday by U.S. Government agencies. When a holiday falls on a Saturday, the preceding Friday shall be observed as a legal holiday by U.S. Government agencies. Also included would be any other day specifically declared by the President of the United States as a National Holiday.

11. OVERTIME AND HOLIDAYS:

Any overtime or holiday pay that may be entitled to Contractor personnel performing under this contract shall be the sole responsibility of the Contractor and shall not be billed to nor reimbursed by the Government.

12. CHANGES TO CONTRACT:

Only those items specified herein are authorized. Before providing any items or support of a non-contractual nature, Contractor shall advise the CO of the reason(s) for the additional work and/or service. Only the Contracting Officer is capable of making modifications to the contract.

13. COMPLAINTS:

Contractor shall promptly and courteously respond to complaints within 3 working days, including complaints brought to Contractor’s attention by the CO. Contractor shall maintain a written record of all complaints, both written and oral, showing the identity of the individual, the nature of the complaint, and Contractor’s response. Contractor shall permit the Government to inspect such records upon reasonable notice.

14. INVOICE REQUIREMENTS:

No advance payments will be authorized.

The Government shall pay the Contractor, upon the submission of a properly prepared invoice for prices stipulated in this contract for services and supplies delivered and accepted.

The invoice shall be itemized to include the following minimum information:

Invoice Number and Date.

Contract Number.

Purchase Order/Obligation Number (to be assigned upon task order award).

Date of service.

Itemized list of costs including drugs used, materials, and patient fees.

15. SECURITY REQUIRMENTS:

A. Contractors, contractor personnel, subcontractors, and subcontractor personnel shall be subject to the same Federal laws, regulations, standards, and VA Directives and Handbooks as VA and VA personnel regarding information and information system security.

B. A prohibition on unauthorized disclosure: "Information made available to the contractor or subcontractor by VA for the performance or administration of this contract or information developed by the contractor in performance or administration of the contract shall be used only for those purposes and shall not be used in any other way without the prior written agreement of the VA." See VA Handbook 6500.6, Appendix C, paragraph 3.a.

C. A requirement for data breach notification: Upon discovery of any known or suspected security/privacy incidents, or any unauthorized disclosure of sensitive information, including that contained in system(s) to which the contractor/subcontractor has access, the contractor/subcontractor shall immediately and simultaneously notify the Facility POC, the designated ISO, and Privacy Officer for the contract. The term 'security incident' means an event that has, or could have, resulted in unauthorized access to, loss or damage to VA assets, or sensitive information, or an action that breaches VA security procedures. See VA Handbook 6500.6, Appendix C, paragraph 6.a.

D. A requirement to pay liquidated damages in the event of a data breach: "In the event of a data breach or privacy incident involving any SPI the contractor processes or maintains under this contract, the contractor shall be liable to VA for liquidated damages for a specified amount per affected individual to cover the cost of providing credit protection services to those individuals." See VA Handbook 6500.6, Appendix C, paragraph 7.a., 7.d.

E. A requirement for annual security/privacy awareness training: "Before being granted access to VA information or information systems, all contractor employees and subcontractor employees requiring such access shall complete on an annual basis either: (i) the VA security/privacy awareness training (contains VA's security/privacy requirements) within 1 week of the initiation of the contract, or (ii) security awareness training provided or arranged by the contractor that conforms to VA's security/privacy requirements as delineated in the hard copy of the VA security awareness training provided to the contractor. If the contractor provides their own training that conforms to VA's requirements, they will provide the Facility POC or CO, a yearly report (due annually on the date of the contract initiation) stating that all applicable employees involved in VA's contract have received their annual security/privacy training that meets VA's requirements and the total number of employees trained. See VA Handbook 6500.6, Appendix C, paragraph 9.

F. A requirement to sign VA's Rules of Behavior: "Before being granted access to VA information or information systems, all contractor employees and subcontractor employees requiring such access shall sign on an annual basis an acknowledgment that they have read, understand, and agree to abide by VA's Contractor Rules of Behavior which is attached to this contract." See VA Handbook 6500.6, Appendix C, paragraph 9, Appendix D. Note: If a medical device vendor anticipates that the services under the contract will be performed by 10 or more individuals, the Contractor Rules of Behavior may be signed by the vendor's designated representative. The contract must reflect by signing the Rules of Behavior on behalf of the vendor that the designated representative agrees to ensure that all such individuals review and understand the Contractor Rules of Behavior when accessing VA's information and information systems.

G. Bio-Medical devices and other equipment or systems containing media (hard drives, optical disks, etc.) with VA sensitive information must not be returned to the vendor at the end of lease, for trade-in, or other purposes." See VA Handbook 6500.6, Appendix C, paragraph 5.h., for the specific options.

16. RECORDS MANAGEMENT LANGUAGE

Contractor shall comply with all applicable records management laws and regulations, as well as National Archives and Records Administration (NARA) records policies, including but not limited to the Federal Records Act (44 U.S.C. Chapters. 21, 29, 31, 33), NARA regulations at 36 CFR Chapter XII Subchapter B, and those policies associated with the safeguarding of records covered by the Privacy Act of 1974 (5 U.S.C. 552a). These policies include the preservation of all records, regardless of form or characteristics, mode of transmission, or state of completion.

In accordance with 36 CFR 1222.32, all data created for Government use and delivered to, or falling under the legal control of, the Government are Federal records subject to the provisions of 44 U.S.C. chapters 21, 29, 31, and 33, the Freedom of Information Act (FOIA) (5 U.S.C. 552), as amended, and the Privacy Act of 1974 (5 U.S.C. 552a), as amended and must be managed and scheduled for disposition only as permitted by statute or regulation.

In accordance with 36 CFR 1222.32, the contractor shall maintain all records created for Government use or created in the course of performing the contract and/or delivered to, or under the legal control of the Government and must be managed in accordance with Federal law. Electronic records and associated metadata must be accompanied by sufficient technical documentation to permit understanding and use of the records and data.

The VA Southern Nevada Healthcare System (VASNHCS) and its contractors are responsible for preventing the alienation or unauthorized destruction of records, including all forms of mutilation. Records may not be removed from the legal custody of VASNHCS or destroyed except for in accordance with the provisions of the agency records schedules and with the written concurrence of the Head of the Contracting Activity. Willful and unlawful destruction, damage or alienation of Federal records is subject to the fines and penalties imposed by 18 U.S.C. 2701.

In the event of any unlawful or accidental removal, defacing, alteration, or destruction of records, the contractor must report to VASNHCS. The agency must report promptly to NARA in accordance with 36 CFR 1230.

The contractor shall immediately notify the appropriate Contracting Officer (CO) upon discovery of any inadvertent or unauthorized disclosures of information, data, documentary materials, records or equipment. Disclosure of non-public information is limited to authorized personnel with a need-to-know as described in the contract documents. The contractor shall ensure that the appropriate personnel, administrative, technical, and physical safeguards are established to ensure the security and confidentiality of this information, data, documentary material, records and/or equipment is properly protected. The contractor shall not remove material from Government facilities or systems, or facilities or systems operated or maintained on the Government’s behalf, without the express written permission of the Head of the Contracting Activity. When information, data, documentary material, records and/or equipment is no longer required, it shall be returned to VASNHCS control or the contractor must hold it until otherwise directed. Items returned to the Government shall be hand carried, mailed, emailed, or securely electronically transmitted to the CO or address prescribed in the contract documents. Destruction of records is EXPRESSLY PROHIBITED unless in accordance with Paragraph (4).

The contractor is required to obtain the CO's approval prior to engaging in any contractual relationship (sub-contractor) in support of this contract requiring the disclosure of information, documentary material and/or records generated under, or relating to, contracts. The contractor (and any sub-contractor) is required to abide by Government and VASNHCS guidance for protecting sensitive, proprietary information, classified, and controlled unclassified information.

The contractor shall only use Government IT equipment for purposes specifically tied to or authorized by the contract and in accordance with VASNHCS policy.

The contractor shall not create or maintain any records containing any non-public VASNHCS information that are not specifically tied to or authorized by the contract.

The contractor shall not retain, use, sell, or disseminate copies of any deliverable that contains information covered by the Privacy Act of 1974 or that which is generally protected from public disclosure by an exemption to the FOIA.

VASNHCS owns the rights to all data and records produced as part of this contract. All deliverables under the contract are the property of the U.S. Government for which VASNHCS shall have unlimited rights to use, dispose of, or disclose such data contained therein as it determines to be in the public interest. Any contractor rights in the data or deliverables must be identified as required by FAR 52.227-11 through FAR 52.227-20.

Training. All contractor employees assigned to this contract who create, work with, or otherwise handle records are required to take VHA-provided records management training. The contractor is responsible for confirming training has been completed according to agency policies, including initial training and any annual or refresher training.

17. FLOWDOWN OF REQUIREMENTS TO SUBCONTRACTORS

The contractor shall incorporate the substance of this clause, its terms and requirements including this paragraph, in all subcontracts under this contract document, and require written subcontractor acknowledgment of same.

Violation by a subcontractor of any provision set forth in this clause will be attributed to the contractor.

B.3 PRICE/COST SCHEDULE

The Contractor shall furnish Hazardous Pharmaceutical Compounding for the Department of Veterans Affairs in accordance with the specifications listed herein.

The guaranteed minimum award amount for this contract is $10,000.00. The maximum aggregate value of orders that can be placed under this contract is $2,750,000.00. The Government does not guarantee that it will place any orders under this contract in excess of the guaranteed minimum award amount.

ITEM INFORMATION

Ado-trastuzumab emtansine 100mg Contract Period: Ordering Period 1 POP Begin: 02-01-2024 POP End: 09-30-2024 PRINCIPAL NAICS CODE: 325412 - Pharmaceutical Preparation Manufacturing PRODUCT/SERVICE CODE: 6505 - Drugs and Biologicals

Ado-trastuzumab emtansine 160mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Atezoliumab 1200mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Azacitidine 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Bendamustine 100mg Belrapzo

POP Begin: 02-01-2024 POP End: 09-30-2024

Bendamustine 100mg Bendeka

POP Begin: 02-01-2024 POP End: 09-30-2024

Bevacizumab 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Bevacizumab 400mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Bevacizumab-awwb 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Bevacizumab-awwb 400mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Bevacizumab-bvzr 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Bevacizumab-bvzr 400mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Bleomycin 15 units

POP Begin: 02-01-2024 POP End: 09-30-2024

Bleomycin 30 units

POP Begin: 02-01-2024 POP End: 09-30-2024

Bortezomib 3.5mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Bortezomib 3.5mg Velcade

POP Begin: 02-01-2024 POP End: 09-30-2024

Brentuximab vedotin 50mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Cabazitaxel 60mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Carboplatin 150mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Carboplatin 50mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Carboplatin 600mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Carfilzomib 60mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Cetuximab 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Cisplatin 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Cisplatin 50mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Cyclophosphamide 1g

POP Begin: 02-01-2024 POP End: 09-30-2024

Cyclophosphamide 2g

POP Begin: 02-01-2024 POP End: 09-30-2024

Cyclophosphamide 500mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Dacarbazine 200mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Daratumumab 400mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Daratumumab100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Decitabine 50mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Dextrose 5% 1000ml

POP Begin: 02-01-2024 POP End: 09-30-2024

Dextrose 5% 100ml

POP Begin: 02-01-2024 POP End: 09-30-2024

Dextrose 5% 250ml

POP Begin: 02-01-2024 POP End: 09-30-2024

Dextrose 5% 500ml

POP Begin: 02-01-2024 POP End: 09-30-2024

Docetaxel 160mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Docetaxel 20mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Docetaxel 80mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Docetaxel 80mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Doxorubicin 20mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Doxorubicin 50mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Durvalumab 120mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Durvalumab 500mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Eculizumab 300mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Elotuzumab 300mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Elotuzumab 400mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Etoposide 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Etoposide Phosphate 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Fam-trastuzumab deruxtecan-nxki 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Fluorouracil 1g

POP Begin: 02-01-2024 POP End: 09-30-2024

Fluorouracil 500mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Fluorouracil 5g

POP Begin: 02-01-2024 POP End: 09-30-2024

Fosaprepitant 150mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Gemcitabine 1g

POP Begin: 02-01-2024 POP End: 09-30-2024

Gemcitabine 200mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Idarubicin 10mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Idarubicin 20mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Idarubicin 5mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Ifosfamide 1g

POP Begin: 02-01-2024 POP End: 09-30-2024

Ifosfamide 3g

POP Begin: 02-01-2024 POP End: 09-30-2024

Infliximab 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Infliximab-abda 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Infliximab-dyyb 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Irinotecan 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Leucovorin 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Leucovorin 350mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Liposomal Doxorubicin 20mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Liposomal Doxorubicin 50mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Liposomal Irinotecan 4.3mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Lurbinectedin 4mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Mesna 1g

POP Begin: 02-01-2024 POP End: 09-30-2024

Methotrexate 1g

POP Begin: 02-01-2024 POP End: 09-30-2024

Methotrexate 250mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Methotrexate 50mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Mitomycin 20mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Mitomycin 40mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Mitomycin 5mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Nivolumab 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Nivolumab 240mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Nivolumab 40mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Ocrelizumab 300mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Oxaliplatin 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Oxaliplatin 50mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Paclitaxel 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Paclitaxel 300mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Paclitaxel 30mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Paclitaxel Protein-Bound 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Paclitaxel Protein-Bound 100mg Abraxane

POP Begin: 02-01-2024 POP End: 09-30-2024

Pamidronate 30mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Pamidronate 90mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Panitumumab 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Panitumumab 400mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Pembrolizumab 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Pemetrexed 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Pemetrexed 100mg Alimta

POP Begin: 02-01-2024 POP End: 09-30-2024

Pemetrexed 500mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Pemetrexed 500mg Alimta

POP Begin: 02-01-2024 POP End: 09-30-2024

Pertuzumab 420mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Polatuzumab Vedotin-piiq 30mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Ramucirumab 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Ramucirumab 500mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Risankizumab-rzaa 150mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Rituximab 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Rituximab 500mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Rituximab-abbs 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Rituximab-abbs 500mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Rituximab-pvvr 100mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Rituximab-pvvr 500mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Sodium Chloride 0.9% 1000ml

POP Begin: 02-01-2024 POP End: 09-30-2024

Sodium Chloride 0.9% 100ml

POP Begin: 02-01-2024 POP End: 09-30-2024

Sodium Chloride 0.9% 250ml

POP Begin: 02-01-2024 POP End: 09-30-2024

Sodium Chloride 0.9% 500ml

POP Begin: 02-01-2024 POP End: 09-30-2024

Sterile Water 1000ml

POP Begin: 02-01-2024 POP End: 09-30-2024

Sterile Water 250ml

POP Begin: 02-01-2024 POP End: 09-30-2024

Sterile Water 500ml

POP Begin: 02-01-2024 POP End: 09-30-2024

Trastuzumab 150mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Trastuzumab-qyyp 420mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Vedolizumab 300mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Vinblastine 10mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Vincristine 1mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Vincristine 2mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Zoledronic Acid 4mg

POP Begin: 02-01-2024 POP End: 09-30-2024

Facility Patient Fee (USP 797, 800, Delivery)

POP Begin: 02-01-2024 POP End: 09-30-2024

Intrathecal Mixing

POP Begin: 02-01-2024 POP End: 09-30-2024

STAT Order

POP Begin: 02-01-2024 POP End: 09-30-2024

Ado-trastuzumab emtansine 100mg Contract Period: Ordering Period 2 POP Begin: 10-01-2024 POP End: 09-30-2025

Ado-trastuzumab emtansine 160mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Atezoliumab 1200mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Azacitidine 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Bendamustine 100mg Belrapzo

POP Begin: 10-01-2024 POP End: 09-30-2025

Bendamustine 100mg Bendeka

POP Begin: 10-01-2024 POP End: 09-30-2025

Bevacizumab 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Bevacizumab 400mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Bevacizumab-awwb 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Bevacizumab-awwb 400mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Bevacizumab-bvzr 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Bevacizumab-bvzr 400mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Bleomycin 15 units

POP Begin: 10-01-2024 POP End: 09-30-2025

Bleomycin 30 units

POP Begin: 10-01-2024 POP End: 09-30-2025

Bortezomib 3.5mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Bortezomib 3.5mg Velcade

POP Begin: 10-01-2024 POP End: 09-30-2025

Brentuximab vedotin 50mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Cabazitaxel 60mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Carboplatin 150mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Carboplatin 50mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Carboplatin 600mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Carfilzomib 60mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Cetuximab 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Cisplatin 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Cisplatin 50mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Cyclophosphamide 1g

POP Begin: 10-01-2024 POP End: 09-30-2025

Cyclophosphamide 2g

POP Begin: 10-01-2024 POP End: 09-30-2025

Cyclophosphamide 500mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Dacarbazine 200mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Daratumumab 400mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Daratumumab100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Decitabine 50mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Dextrose 5% 1000ml

POP Begin: 10-01-2024 POP End: 09-30-2025

Dextrose 5% 100ml

POP Begin: 10-01-2024 POP End: 09-30-2025

Dextrose 5% 250ml

POP Begin: 10-01-2024 POP End: 09-30-2025

Dextrose 5% 500ml

POP Begin: 10-01-2024 POP End: 09-30-2025

Docetaxel 160mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Docetaxel 20mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Docetaxel 80mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Docetaxel 80mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Doxorubicin 20mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Doxorubicin 50mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Durvalumab 120mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Durvalumab 500mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Eculizumab 300mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Elotuzumab 300mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Elotuzumab 400mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Etoposide 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Etoposide Phosphate 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Fam-trastuzumab deruxtecan-nxki 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Fluorouracil 1g

POP Begin: 10-01-2024 POP End: 09-30-2025

Fluorouracil 500mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Fluorouracil 5g

POP Begin: 10-01-2024 POP End: 09-30-2025

Fosaprepitant 150mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Gemcitabine 1g

POP Begin: 10-01-2024 POP End: 09-30-2025

Gemcitabine 200mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Idarubicin 10mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Idarubicin 20mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Idarubicin 5mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Ifosfamide 1g

POP Begin: 10-01-2024 POP End: 09-30-2025

Ifosfamide 3g

POP Begin: 10-01-2024 POP End: 09-30-2025

Infliximab 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Infliximab-abda 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Infliximab-dyyb 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Irinotecan 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Leucovorin 100mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Leucovorin 350mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Liposomal Doxorubicin 20mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Liposomal Doxorubicin 50mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Liposomal Irinotecan 4.3mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Lurbinectedin 4mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Mesna 1g

POP Begin: 10-01-2024 POP End: 09-30-2025

Methotrexate 1g

POP Begin: 10-01-2024 POP End: 09-30-2025

Methotrexate 250mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Methotrexate 50mg

POP Begin: 10-01-2024 POP End: 09-30-2025

Mitomycin 20mg

POP Begin: 10-01-2024 POP End: 09-30-2025